Wells Fargo
VOR icon

Wells Fargo’s Vor Biopharma VOR Stock Holding History

Wells Fargo’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$668K Buy
36,273
+36,272
+3,627,200% +$549K ﹤0.01% 4405
2026
Q1 		$18 Hold
1
– – ﹤0.01% 6830
2025
Q4 		$13 Hold
1
– – ﹤0.01% 6834
2025
Q3 		$49 Buy
+1
New +$40 ﹤0.01% 6495
2024
Q2 		– Sell
-674
Closed -$32K – 7503
2024
Q1 		$32K Buy
674
+93
+16% +$4.08K ﹤0.01% 5425
2023
Q4 		$26.1K Buy
581
+115
+25% +$4.75K ﹤0.01% 5541
2023
Q3 		$19.8K Sell
466
-250
-35% -$13.6K ﹤0.01% 5604
2023
Q2 		$44.2K Buy
716
+705
+6,409% +$64.4K ﹤0.01% 5469
2023
Q1 		$1.19K Buy
11
+5
+83% +$554 ﹤0.01% 6331
2022
Q4 		$771 Hold
6
– – ﹤0.01% 6270
2022
Q3 		$0 Buy
6
+2
+50% +$197 ﹤0.01% 7447
2022
Q2 		$0 Sell
4
-17
-81% -$1.74K ﹤0.01% 7575
2022
Q1 		$3K Sell
21
-337
-94% -$57.4K ﹤0.01% 6606
2021
Q4 		$83K Buy
358
+356
+17,800% +$103K ﹤0.01% 5736
2021
Q3 		$0 Sell
2
-2
-50% -$595 ﹤0.01% 7582
2021
Q2 		$2K Sell
4
-174
-98% -$85.9K ﹤0.01% 6568
2021
Q1 		$153K Buy
+178
New +$151K ﹤0.01% 5287

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Wells Fargo's VOR Position: Q2 2026 in Review

Wells Fargo increased its Vor Biopharma (VOR) stake by 3,627,200% in Q2 2026, buying an estimated $549K and bringing the position to 36,273 shares worth $668K. The position accounts for ﹤0.01% of the portfolio, ranked #4405.

Wells Fargo first reported a position in VOR in Q1 2021 and has held it in 17 quarters since. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Wells Fargo held 36,273 shares of Vor Biopharma worth $668K as of Q2 2026.
  • Wells Fargo bought 36,272 Vor Biopharma shares in Q2 2026, an estimated $549K.
  • Vor Biopharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4405 holding.
  • Wells Fargo first reported a position in Vor Biopharma in Q1 2021 and has held it in 17 quarters since.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.